Noven Pharmaceuticals, Inc. Strategy, SWOT and Corporate Finance Report
Summary
Noven Pharmaceuticals, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.
Key Highlights
Noven Pharmaceuticals, Inc. Noven or 'the company' develops and sells prescription pharmaceutical products which are marketed under Minivelle, Combipatch and Daytrana brands. These products treat deficit hyperactivity disorder ADHD, womens diseases and central nervous systems disorders. Noven maintains stateofthe art, FDAapproved transdermal manufacturing facilities in Miami which are also approved by the U.S. DEA Drug Enforcement Agency for the production of controlled substances. The company is headquartered in Miami, Florida, the US.
Scope
Detailed information on Noven Pharmaceuticals, Inc. required for business and competitor intelligence needs
A study of the major internal and external factors affecting Noven Pharmaceuticals, Inc. in the form of a SWOT analysis
An indepth view of the business model of Noven Pharmaceuticals, Inc. including a breakdown and examination of key business segments
Intelligence on Noven Pharmaceuticals, Inc.'s mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about Noven Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
Large number of easytograsp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Noven Pharmaceuticals, Inc. and the factors that influence its strategies.
Track strategic initiatives of the company and latest corporate news and actions.
Assess Noven Pharmaceuticals, Inc. as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Noven Pharmaceuticals, Inc.'s business structure, strategy and prospects.